They found that anti-PD-1: (1) decreased tumor burden, (2) reversed immunosuppression by increasing tumor dendritic cell content and M1 tumor-associated macrophages (TAMs) and decreasing immunosuppressive protumoral M2 macrophages, (3) increased antitumor responsiveness of M1 macrophages, dendritic cells, and CD8+ T cells, (4) and increased the diversity of the gut microbiome previously shown to influence ICB response in cancers [183]. The gene discussed is CD8A; the disease is neoplasm.